ArticleClinical and vaccine immunology : CVI2016
Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.
Article in Clinical and vaccine immunology : CVI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Sero-epidemiological studies of pathogen burden: A scoping review.Wellcome open research · 2026Pooled it
- Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein-Barr virus.Biomedical journal · 2021Pooled it
- Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes.Scientific reports · 2017Trial
- Causal Effects Between Antibody-Mediated Immune Responses and Parkinson's Disease: Insights from Genetic Studies.Cureus · 2026Article
- Amoxicillin-Induced Hypersensitivity Versus Viral Exanthem in Epstein-Barr Virus Infection: A Paediatric Case Series.Cureus · 2025Article
- High IgG titers against EBV glycoprotein 42 correlate with lower risk of nasopharyngeal carcinoma.The Journal of clinical investigation · 2025Article
- Research landmarks on the 60th anniversary of Epstein-Barr virus.Science China. Life sciences · 2025Review
- TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice.Emerging microbes & infections · 2024Article
- Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.BMC infectious diseases · 2023Article
- Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice.Nature communications · 2023Article
- Review
- A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus.Virology journal · 2022Article
- Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction.Vaccines · 2021Review
- Conserved Gammaherpesvirus Protein Kinase Counters the Antiviral Effects of Myeloid Cell-Specific STAT1 Expression To Promote the Establishment of Splenic B Cell Latency.Journal of virology · 2021Article
- Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays.Cells · 2021Article
- Maternal Epstein-Barr Virus-Specific Antibodies and Risk of Infection in Ugandan Infants.The Journal of infectious diseases · 2021Article
- Article
- Epstein-Barr Virus Promotes B Cell Lymphomas by Manipulating the Host Epigenetic Machinery.Cancers · 2020Review
- Seroprevalence of Epstein-Barr virus among children and adults in Tehran, Iran.New microbes and new infections · 2020Article
- An updated review on activated PI3 kinase delta syndrome (APDS).Genes & diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Prospective studies of antibodies to multiple Epstein-Barr virus (EBV) proteins and EBV neutralizing antibodies in the same individuals before, during, and after primary EBV infection have not been reported. We studied antibody responses to EBV in college students who acquired primary EBV infection during prospective surveillance and correlated the kinetics of antibody response with the severity of disease. Neutralizing antibodies and enzyme-linked immunosorbent assay (ELISA) antibodies to gp350, the major target of neutralizing antibody, reached peak levels at medians of 179 and 333 days after the onset of symptoms of infectious mononucleosis, respectively. No clear correlation was found between the severity of the symptoms of infectious mononucleosis and the peak levels of antibody to individual viral proteins or to neutralizing antibody. In summary, we found that titers of neutralizing antibody and antibodies to multiple EBV proteins increase over many months after primary infection with EBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.